BackPPOLYMARKET

Will the FDA reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by December 31, 2026?

Yes 48.0%

Vol$2.8K

SnapshotOct 29, 2026, 12:00 AM UTC

Yes 48.0%

TradeTrade on Polymarket

Event

MarketPOLYMARKETactive

MarketPOLYMARKETactiveHealth

Will the FDA reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by December 31, 2026?

Part of: When will the FDA reclassify BPC-157 to Category 1?

YesYes Price

48.0¢

VolTotal Volume

$2.8K

Outcomes

Ends

Jan 1, 2027, 4:59 AM UTC

Trade on Polymarket

Will the FDA reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by December 31, 2026?

Yes

48.0¢

Vol

$2.8K

Outcomes

Trade

Yes48.0¢

No52.0¢

Outcome

Yes quoted price: 48.0%. Snapshot Oct 29, 2026, 12:00 AM UTC. History may have a different observation time.

Price History

Will the FDA reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by December 31, 2026? · Yes

No historical data available

Price history will appear here when available

Rules and settlement

Listed close: Jan 1, 2027, 4:59 AM UTC. Settlement follows the provider's contract terms and may occur later.

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.

Read this contract on Polymarket

Resolution Info